The Spot Sign and Tranexamic Acid on Preventing ICH Growth – AUStralasia Trial (STOP-AUST): Protocol of a Phase II Randomized,Placebo-Controlled,Double-Blind,Multicenter Trial

Abstract

Rationale

No evidence-based acute therapies exist for intracerebral hemorrhage. Intracerebral hemorrhage growth is an important determinant of patient outcome. Tranexamic acid is known to reduce hemorrhage in other conditions.

Aim

The study aims to test the hypothesis that intracerebral hemorrhage patients selected with computed tomography angiography contrast extravasation ‘spot sign’ will have lower rates of hematoma growth when treated with intravenous tranexamic acid within 4·5-hours of stroke onset compared with placebo.

Design

The Spot sign and Tranexamic acid On Preventing ICH growth – AUStralasia Trial is a multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled, investigator-initiated, academic Phase II trial. Intracerebral hemorrhage patients fulfilling clinical criteria (e.g. Glasgow Coma Scale >7, intracerebral hemorrhage volume <70 ml, no identified secondary cause of intracerebral hemorrhage, no thrombotic events within the previous 12 months, no planned surgery) and demonstrating contrast extravasation on computed tomography angiography will receive either intravenous tranexamic acid 1 g 10-min bolus followed by 1 g eight-hour infusion or placebo. A second computed tomography will be performed at 24 ± 3 hours to evaluate intracerebral hemorrhage growth and patients followed up for three-months.

Study outcomes

The primary outcome measure is presence of intracerebral hemorrhage growth by 24 ± 3 hours, defined as either >33% or >6 ml increase from baseline, and will be adjusted for baseline intracerebral hemorrhage volume. Secondary outcome measures include growth as a continuous measure, thromboembolic events, and the three-month modified Rankin Scale score.

Discussion

This is the first trial to evaluate the efficacy of tranexamic acid in intracerebral hemorrhage patients selected based on an imaging biomarker of high likelihood of hematoma growth. The trial is registered as NCT01702636.

Keywords

ICH intracerebral hemorrhage spot sign tranexamic acid

Get full access to this article

View all access options for this article.

References

Strong

Mathers

Bonita

. Preventing stroke: Saving lives around the world. Lancet Neurol 2007; 6: 182–7.

Lees

Bluhmki

Von Kummer

. Time to treatment with intravenous alteplase and outcome in stroke: An updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695–703.

Feigin

Lawes

Bennett

Barker-Collo

Parag

. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: A systematic review. Lancet Neurol 2009; 8: 355–69.

Van Asch

Luitse

Rinkel

Van der Tweel

Algra

Klijn

. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-analysis. Lancet Neurol 2010; 9: 167–76.

Lozano

Naghavi

Foreman

. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–128.

Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. Cochrane Database Syst Rev 2007; (4): CD000197.

Donnan

Hankey

Davis

. Intracerebral haemorrhage: A need for more data and new research directions. Lancet Neurol 2010; 9: 133–4.

Morgenstern

Hemphill

3rd Anderson

. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2010; 41: 2108–29.

Steiner

Petersson

Al-Shahi

Salman R

. European research priorities for intracerebral haemorrhage. Cerebrovasc Dis 2011; 32: 409–19.

10.

Hemphill

3rd Farrant

Neill

Jr . Prospective validation of the ICH Score for 12-month functional outcome. Neurology 2009; 73: 1088–94.

11.

Meretoja

Strbian

Putaala

. SMASH-U: A proposal for etiologic classification of intracerebral hemorrhage. Stroke 2012; 43: 2592–7.

12.

Brott

Broderick

Kothari

. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997; 28: 1–5.

13.

Davis

Broderick

Hennerici

. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66: 1175–81.

14.

Delcourt

Huang

Arima

. Hematoma growth and outcomes in intracerebral hemorrhage: The INTERACT1 study. Neurology 2012; 79: 314–19.

15.

Mayer

Brun

Begtrup

. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777–85.

16.

Mayer

Brun

Begtrup

. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358: 2127–37.

17.

Wada

Aviv

Fox

. CT angiography ‘spot sign’ predicts hematoma expansion in acute intracerebral hemorrhage. Stroke 2007; 38: 1257–62.

18.

Goldstein

Fazen

Snider

. Contrast extravasation on CT angiography predicts hematoma expansion in intracerebral hemorrhage. Neurology 2007; 68: 889–94.

19.

Demchuk

Dowlatshahi

Rodriguez-Luna

. Prediction of haematoma growth and outcome in patients with intracerebral haemorrhage using the CT-angiography spot sign (PREDICT): A prospective observational study. Lancet Neurol 2012; 11: 307–14.

20.

Gladstone

Aviv

Demchuk

. ‘Spot Sign’ Selection of Intracerebral Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT). Available at http://clinicaltrials.gov/ct2/show/NCT01359202 (accessed May 23, 2013).

21.

Flaherty

Jauch

. The Spot Sign for Predicting and Treating ICH Growth Study (STOP-IT). Available at http://clinicaltrials.gov/ct2/show/NCT00810888 (accessed May 23, 2013).

22.

Ghinea

Lipworth

Kerridge

Day

. No evidence or no alternative? Taking responsibility for off-label prescribing. Intern Med J 2012; 42: 247–51.

23.

Mannucci

. Hemostatic drugs. N Engl J Med 1998; 339: 245–53.

24.

Shakur

Roberts

Bautista

. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010; 376: 23–32.

25.

Roberts

Shakur

Afolabi

. The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096–101.

26.

Parsons

Christensen

. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke 2012; 7: 74–80.

27.

Mehta

Pocock

. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Stat Med 2011; 30: 3267–84.

28.

Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics (DRAFT). U.S. Department of Health and Human Services, 2010. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM201790.pdf (accessed May 23, 2013).

29.

Altman

Schulz

Moher

. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001; 134: 663–94.

30.

Goldstein

Simel

. Is this patient having a stroke? JAMA 2005; 293: 2391–402.

31.

Brouwers

Falcone

McNamara

. CTA spot sign predicts hematoma expansion in patients with delayed presentation after intracerebral hemorrhage. Neurocrit Care 2012; 17: 421–8.

32.

Ederies

Demchuk

Chia

. Postcontrast CT extravasation is associated with hematoma expansion in CTA spot negative patients. Stroke 2009; 40: 1672–6.

33.

Maramattom

Manno

Fulgham

Jaffe

Wijdicks

. Clinical importance of cardiac troponin release and cardiac abnormalities in patients with supratentorial cerebral hemorrhages. Mayo Clin Proc 2006; 81: 192–6.

34.

Perel

Al-Shahi

Salman R

Constain

. Effect of tranexamic acid in traumatic brain injury: A nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011; 343: d3795.

35.

Van Rossum

Wintzen

Endtz

Schoen

De Jonge

. Effect of tranexamic acid on rebleeding after subarachnoid hemorrhage: A double-blind controlled clinical trial. Ann Neurol 1977; 2: 238–42.

36.

Fodstad

Liliequist

Schannong

Thulin

. Tranexamic acid in the preoperative management of ruptured intracranial aneurysms. Surg Neurol 1978; 10: 9–15.

37.

Chandra

. Treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm with tranexamic acid: A double-blind clinical trial. Ann Neurol 1978; 3: 502–4.

38.

Kaste

Ramsay

. Tranexamic acid in subarachnoid hemorrhage. A double-blind study. Stroke 1979; 10: 519–22.

39.

Vermeulen

Lindsay

Murray

. Antifibrinolytic treatment in subarachnoid hemorrhage. N Engl J Med 1984; 311: 432–7.

40.

Roos

. Antifibrinolytic treatment in subarachnoid hemorrhage: A randomized placebo-controlled trial. STAR Study Group. Neurology 2000; 54: 77–82.

41.

Roos

Rinkel

Vermeulen

Algra

Van Gijn

. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 2003; (2): CD001245.

42.

Hillman

Fridriksson

Nilsson

Saveland

Jakobsson

. Immediate administration of tranexamic acid and reduced incidence of early rebleeding after aneurysmal subarachnoid hemorrhage: A prospective randomized study. J Neurosurg 2002; 97: 771–8.

43.

Sprigg

. A randomised controlled trial of Tranexamic acid in Intracerebral Haemorrhage (TICH). Available at http://www.controlled-trials.com/ISRCTN50867461 (accessed May 23, 2013).

44.

Sprigg

Hogg

Dineen

Bath

. Tranexamic acid for acute Intracerebral Haemorrhage (TICH): Baseline characteristics of enrolled patients in a randomised controlled trial. [POSTER presented at the European Stroke Conference 24 May 2012]. Cerebrovasc Dis 2012; 33: 726–7.

45.

Sorimachi

Fujii

Morita

Tanaka

. Rapid administration of antifibrinolytics and strict blood pressure control for intracerebral hemorrhage. Neurosurgery 2005; 57: 837–44.

46.

Sorimachi

Fujii

Morita

Tanaka

. Predictors of hematoma enlargement in patients with intracerebral hemorrhage treated with rapid administration of antifibrinolytic agents and strict blood pressure control. J Neurosurg 2007; 106: 250–4.